The real-life effectiveness of palivizumab for reducing hospital admissions for respiratory syncytial virus in infants residing in Nunavut

Canadian Respiratory Journal

Volumn 21, Issue 3, 2014, Pages 185-189

  Banerji, Anna ^a   Panzov, Vladimir ^a   Young, Michael ^b   Lee, Bonita E ^c   Mamdani, Muhammad ^a   Giles, B Louise ^d   Dennis, Marguerite ^e   Morel, Johanne ^f   Bisson, Danny ^g   Paes, Bosco A ^h   Hui, Charles ⁱ   Mahony, Jim ^j  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b IWK Children's Hospital   (Canada)

^c Canada Edmonton Clinic Health Academy (ECHA)   (Canada)

^d CHILDREN S HOSPITAL RESEARCH INSTITUTE OF MANITOBA   (Canada)

^e SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^f MONTREAL CHILDREN S HOSPITAL   (Canada)

^g JA Hildes Northern Medical Unit   (Canada)

^h MCMASTER UNIVERSITY   (Canada)

ⁱ CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^j MCMASTER UNIVERSITY   (Canada)

more..

Author keywords

Effectiveness; Inuit; Nunavut; Palivizumab; Respiratory syncytial virus

Indexed keywords

PALIVIZUMAB; ANTIVIRUS AGENT; MONOCLONAL ANTIBODY;

ARTICLE; CANADA; DRUG EFFICACY; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INFANT; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROPHYLAXIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; CLINICAL TRIAL; ETHNOLOGY; HEALTH SURVEY; INFANT, PREMATURE, DISEASES; INUIT; MULTICENTER STUDY; NEWBORN; PREMATURITY; PROSPECTIVE STUDY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIVIRAL AGENTS; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; INUITS; NUNAVUT; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; TREATMENT OUTCOME;

EID: 84903883086     PISSN: 11982241     EISSN: None     Source Type: Journal    
DOI: 10.1155/2014/941367     Document Type: Article

References (30)

1. Langley JM, Wang EE, Law BJ, et al. Economic evaluation of respiratory syncytial virus infection in Canadian children: A Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study. J Pediatr 1997;131:113-7. (Pubitemid 27498318)
2. Mandell G, Bennett J, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 7th edn. Philadelphia: Elsevier 2010.
3. Leader S, Kohlhase K. Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. J Pediatr 2003;143(5 Suppl):S127-32. (Pubitemid 37456910)
4. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 1998;102(3 Pt 1):531-7.
5. Banerji A, Lanctot KL, Paes BA, et al. Comparison of the cost of hospitalization for respiratory syncytial virus disease versus palivizumab prophylaxis in Canadian Inuit infants. Pediatr Infect Dis J 2009;28:702-6.
6. Banerji A, Young M, Northern RSV Surveillance Team, eds. Banerji A. Admission for Lower Respiratory Infections in Inuit Children in the Canadian Arctic: The Northern RSV Surveillance. 4th International Meeting on Indigenous Child Health. Vancouver, March 5, 2011,
7. Banerji A, Young M, northern RSV Surveillance Team, eds. Is an ounce of palivizumab worth a pound of cure? Canadian Immunization Conference, Quebec City, December 6 to 8, 2010.
8. Banerji A. High rates of hospitalisation for bronchiolitis in Inuit children on Baffin Island. Int J Circumpolar Health 2001;60:375-9.
9. Banerji A, Bell A, Mills EL, et al. Lower respiratory tract infections in Inuit infants on Baffin Island. CMAJ 2001;164:1847-50. (Pubitemid 32702069)
10. Singleton RJ, Redding GJ, Lewis TC, et al. Sequelae of severe respiratory syncytial virus infection in infancy and early childhood among Alaska Native children. Pediatrics 2003;112:285-90. (Pubitemid 36951387)
11. Singleton R, Morris A, Redding G, et al. Bronchiectasis in Alaska Native children: Causes and clinical courses. Pediatr Pulmonol 2000;29:182-7. (Pubitemid 30141794)
12. Singleton RJ, Petersen KM, Berner JE, et al. Hospitalizations for respiratory syncytial virus infection in Alaska Native children. Pediatr Infect Dis J 1995;14:26-30.
13. Holman RC, Curns AT, Cheek JE, et al. Respiratory syncytial virus hospitalizations among American Indian and Alaska Native infants and the general United States infant population. Pediatrics 2004;114:e437-44. (Pubitemid 41529740)
14. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: A systematic review and meta-analysis. Lancet 2010;375:1545-55.
15. Meissner HC, Long SS. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 2003;112:1447-52. (Pubitemid 37523438)
16. Palivizumab and respiratory syncytial virus immune globulin intravenous for the prophylaxis of respiratory syncytial virus infection in high risk infants. Paediatr Child Health 1999;4:474-89.
17. Banerji A, Panzov V, Robinson J, Young M, Ng K, Mamdani M. The cost of lower respiratory tract infections hospital admissions in the Canadian Arctic. Int J Circumpolar Health 2013;72(21595).
18. Tam DY, Banerji A, Paes BA, Hui C, Tarride JE, Lanctot KL. The cost effectiveness of palivizumab in term Inuit infants in the Eastern Canadian Arctic. J Med Econ 2009;12:361-70.
19. Banerji A, Greenberg D, White LF, et al. Risk factors and viruses associated with hospitalization due to lower respiratory tract infections in Canadian Inuit children: A case-control study. Pediatr Infect Dis J 2009;28:697-701.
20. Creery D, Lyer P, Samson L, Coyle D, Osborne G, MacDonald A. Costs associated with infant bronchiolitis in the Baffin region of Nunavut. Int J Circumpolar Health 2005;64:38-45.
21. Robinson J. Preventing respiratory syncytial virus infections. Paediatr Child Health 2011;16:487-90.
22. Singleton RJ, Bruden D, Bulkow LR, Varney G, Butler JC. Decline in respiratory syncytial virus hospitalizations in a region with high hospitalization rates and prolonged season. Pediatr Infect Dis J 2006;25:1116-22. (Pubitemid 44900674)
23. Singleton R, Dooley L, Bruden D, Raelson S, Butler JC. Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants. Pediatr Infect Dis J 2003;22:540-5. (Pubitemid 36782194)
24. Statistics Canada. Nunavut (Code 6205) (table). 2006 Community Profiles. 2006 Census. Statistics Canada Catalogue no. 92-591-XWE. Ottawa2007 [cited 2011 November 22, 2011]. 〈www12.statcan.gc.ca/census-recensement/2006/dp-pd/ prof/92-591/index.cfm?Lang=E〉 (Accessed January 2012).
25. Statistics Canada. Births, estimates, by province and territory Ottawa2011 [cited 2011 November 16, 2011]. 〈www40.statcan.gc.ca/l01/cst01/ demo04a-eng.htm〉 (Accessed January 2012).
26. Young M, Kandola K, Mitchell R, Leamon A. Hospital admission rates for lower respiratory tract infections in infants in the Northwest Territories and Kitikmeot region of Nunavut for 2000-2004. Paediatr Child Health 2007;12:563-6. (Pubitemid 350075600)
27. Singleton RJ, Bruden D, Bulkow LR. Respiratory syncytial virus season and hospitalizations in the Alaskan Yukon-Kuskokwim Delta. Pediatr Infectious Dis J 2007;26(11 Suppl):S46-50. (Pubitemid 350295030)
28. Orenstein WA, Bernier RH, Dondero TJ, et al. Field evaluation of vaccine efficacy. Bull World Health Organ 1985;63:1055-68. (Pubitemid 16055438)
29. Banerji A, Young M. The cost of lower respiratory tract Infections hospital admissions in the Canadian Arctic. 15th International Congress on Circumpolar Health. Fairbanks, Alaska, August 6, 2012.
30. Abels S, Nadal D, Stroehle A, Bossart W. Reliable detection of respiratory syncytial virus infection in children for adequate hospital infection control management. J Clin Microbiol 2001;39:3135-9. (Pubitemid 32830305)